Compare Oscar Health Inc (OSCR) vs Blue Owl Capital Inc. Class A Common Stock (OWL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oscar Health Inc vs Blue Owl Capital Inc. Class A Common Stock — how do they compare? Oscar Health Inc trades at $34.17 (market cap $10.43B), while Blue Owl Capital Inc. Class A Common Stock trades at $8.79 (market cap $6.35B). The key difference: Oscar Health Inc is the larger of the two by market cap, and Blue Owl Capital Inc. Class A Common Stock pays a 9.8% dividend while Oscar Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oscar Health Inc for 15 Days and Blue Owl Capital Inc. Class A Common Stock for 0 Days on average.
| OSCR | OWL | |
|---|---|---|
Market Cap | $10.43B | $6.35B |
Volume | 5,467,402 | 15,716,423 |
Sector | Health | Financials |
52-Week High | $34.32 | $17.17 |
52-Week Low | $10.85 | $8.23 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | $6.79B | $10.53B |
Dividend Yield | — | 9.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OSCR trades at $33.79, down 0.65% on the day, with strong technical momentum indicated by bullish moving averages. The company shows impressive revenue growth from $11.7B in 2025 to $15.3B in 2026, turning profitable with $551M net income. Recent analyst upgrades to Strong Buy reflect optimism about expanded market opportunities and margin expansion potential.
The stock presents growth potential with consensus price target of $34.75 offering modest upside. Key risks include rising medical costs threatening profitability and competitive ACA market pressures. Institutional interest remains strong with recent purchases, supporting the bullish technical outlook despite RSI indicating potential near-term overbought conditions.
Blue Owl Capital (OWL) trades at $9.29, down 0.54% on the day, with neutral technical indicators showing support at $9 and resistance at $10. The company reported mixed quarterly earnings, beating expectations in Q4 2025 and Q2 2026 but missing in Q1 2026, with Q3 2026 results pending. Revenue growth remains steady at $2.9B in 2025, projected to $3.0B in 2026, though net margins are thin at 2.71%. Analyst sentiment is positive with 63% buy ratings and a $11.01 consensus target, but private credit fund redemptions and loan quality concerns present headwinds.
OWL offers value at a discount to analyst targets with strong institutional backing, but investors face risks from high P/E valuation (77.42), exposure to private credit volatility, and competitive pressures. The stock's 9.8% dividend yield and embedded fee growth from $31.1B in committed capital support upside, though execution on portfolio quality and redemption management will dictate near-term performance. Neutral outlook with cautious optimism pending Q3 earnings clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →About Blue Owl Capital Inc. Class A Common Stock
Blue Owl Capital Inc. is an alternative asset manager that invests across credit, real assets, and GP strategic capital strategies, providing private capital solutions to businesses and to institutional and individual investors.
Read more on OWL →
